A phase I/II study of GTI-2040 and capecitabine combination therapy in patients with advanced or metastatic renal cell carcinoma (mRCC)
Phase of Trial: Phase I/II
Latest Information Update: 04 Jan 2008
At a glance
- Drugs Capecitabine; LOR 2040
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2008 Status changed from recruiting to completed.
- 05 Sep 2005 New trial record.